WO2017216507A1 - Compounds - Google Patents
Compounds Download PDFInfo
- Publication number
- WO2017216507A1 WO2017216507A1 PCT/GB2016/051794 GB2016051794W WO2017216507A1 WO 2017216507 A1 WO2017216507 A1 WO 2017216507A1 GB 2016051794 W GB2016051794 W GB 2016051794W WO 2017216507 A1 WO2017216507 A1 WO 2017216507A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- disease
- phenyl
- difluoro
- ethoxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 62
- 238000000034 method Methods 0.000 claims abstract description 28
- -1 chloro, bromo, iodo, hydroxy Chemical group 0.000 claims abstract description 19
- AQFWNELGMODZGC-UHFFFAOYSA-N o-ethylhydroxylamine Chemical compound CCON AQFWNELGMODZGC-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 5
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 3
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 3
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 3
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract description 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims abstract description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims abstract description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 238000006243 chemical reaction Methods 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 7
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical group C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 claims description 7
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 230000005855 radiation Effects 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 5
- 238000005755 formation reaction Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 241000701022 Cytomegalovirus Species 0.000 claims description 4
- 208000021642 Muscular disease Diseases 0.000 claims description 4
- 201000009623 Myopathy Diseases 0.000 claims description 4
- 206010047115 Vasculitis Diseases 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 238000003682 fluorination reaction Methods 0.000 claims description 4
- 206010025135 lupus erythematosus Diseases 0.000 claims description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 241001529453 unidentified herpesvirus Species 0.000 claims description 4
- RRHWIFHGRURNJZ-UHFFFAOYSA-N 1-[2-[4-(2,2-difluoro-1-phenylcyclopropyl)phenoxy]ethyl]piperidine Chemical compound FC1(C(C1)(C1=CC=CC=C1)C1=CC=C(C=C1)OCCN1CCCCC1)F RRHWIFHGRURNJZ-UHFFFAOYSA-N 0.000 claims description 3
- LBSRFCDLZCBOSD-UHFFFAOYSA-N 1-[2-[4-(2,2-difluoro-1-phenylcyclopropyl)phenoxy]ethyl]pyrrolidine Chemical compound FC1(C(C1)(C1=CC=CC=C1)C1=CC=C(C=C1)OCCN1CCCC1)F LBSRFCDLZCBOSD-UHFFFAOYSA-N 0.000 claims description 3
- BUXYQPINNKJKBC-UHFFFAOYSA-N 2-[4-(2,2-difluoro-1-phenylcyclopropyl)phenoxy]-N,N-dimethylethanamine Chemical compound FC1(C(C1)(C1=CC=CC=C1)C1=CC=C(C=C1)OCCN(C)C)F BUXYQPINNKJKBC-UHFFFAOYSA-N 0.000 claims description 3
- 230000003111 delayed effect Effects 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- LZFCSSWTJGDATO-UHFFFAOYSA-N 2-[4-(2,2-difluoro-1-phenylcyclopropyl)phenoxy]-N,N-diethylethanamine Chemical compound FC1(C(C1)(C1=CC=CC=C1)C1=CC=C(C=C1)OCCN(CC)CC)F LZFCSSWTJGDATO-UHFFFAOYSA-N 0.000 claims description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 2
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000027496 Behcet disease Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 claims description 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 2
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 102000008946 Fibrinogen Human genes 0.000 claims description 2
- 108010049003 Fibrinogen Proteins 0.000 claims description 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 claims description 2
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 208000031814 IgA Vasculitis Diseases 0.000 claims description 2
- 208000011200 Kawasaki disease Diseases 0.000 claims description 2
- 206010023421 Kidney fibrosis Diseases 0.000 claims description 2
- 241000713666 Lentivirus Species 0.000 claims description 2
- 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 claims description 2
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 2
- 208000029725 Metabolic bone disease Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000004983 Phantom Limb Diseases 0.000 claims description 2
- 206010056238 Phantom pain Diseases 0.000 claims description 2
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims description 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 206010072170 Skin wound Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 208000007814 Unstable Angina Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims description 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 229940012952 fibrinogen Drugs 0.000 claims description 2
- 230000003176 fibrotic effect Effects 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 230000001969 hypertrophic effect Effects 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims description 2
- 210000003000 inclusion body Anatomy 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 244000000056 intracellular parasite Species 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 208000011379 keloid formation Diseases 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 201000004792 malaria Diseases 0.000 claims description 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 201000006938 muscular dystrophy Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 208000002086 myofibrillar myopathy Diseases 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 230000002980 postoperative effect Effects 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 230000010076 replication Effects 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 230000037390 scarring Effects 0.000 claims description 2
- 238000003860 storage Methods 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 230000001629 suppression Effects 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 206010043207 temporal arteritis Diseases 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- 230000029812 viral genome replication Effects 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- GPCDGGKVBPVZCT-UHFFFAOYSA-N 1,1-difluorocyclopropane Chemical class FC1(F)CC1 GPCDGGKVBPVZCT-UHFFFAOYSA-N 0.000 abstract description 14
- 125000005429 oxyalkyl group Chemical group 0.000 abstract description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 230000004900 autophagic degradation Effects 0.000 description 23
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 229960001603 tamoxifen Drugs 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000004293 19F NMR spectroscopy Methods 0.000 description 5
- 150000001629 stilbenes Chemical class 0.000 description 5
- 235000021286 stilbenes Nutrition 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 150000001336 alkenes Chemical class 0.000 description 4
- 150000001412 amines Chemical group 0.000 description 4
- 230000002886 autophagic effect Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000010779 crude oil Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 3
- 210000003934 vacuole Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MZJYQXPULRLGCA-UHFFFAOYSA-N 1,1-dichlorocyclopropane Chemical class ClC1(Cl)CC1 MZJYQXPULRLGCA-UHFFFAOYSA-N 0.000 description 2
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000011368 organic material Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- XLCISDOVNFLSGO-VONOSFMSSA-N phorbol-12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(O)C1(C)C XLCISDOVNFLSGO-VONOSFMSSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 150000003509 tertiary alcohols Chemical class 0.000 description 2
- 238000005979 thermal decomposition reaction Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- LZCMQBRCQWOSHZ-UHFFFAOYSA-N 2-bromo-2,2-difluoroacetic acid Chemical compound OC(=O)C(F)(F)Br LZCMQBRCQWOSHZ-UHFFFAOYSA-N 0.000 description 1
- OAWAZQITIZDJRB-UHFFFAOYSA-M 2-chloro-2,2-difluoroacetate Chemical compound [O-]C(=O)C(F)(F)Cl OAWAZQITIZDJRB-UHFFFAOYSA-M 0.000 description 1
- RAGSWDIQBBZLLL-UHFFFAOYSA-N 2-chloroethyl(diethyl)azanium;chloride Chemical compound Cl.CCN(CC)CCCl RAGSWDIQBBZLLL-UHFFFAOYSA-N 0.000 description 1
- LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 1
- NBJHDLKSWUDGJG-UHFFFAOYSA-N 4-(2-chloroethyl)morpholin-4-ium;chloride Chemical compound Cl.ClCCN1CCOCC1 NBJHDLKSWUDGJG-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 229940073735 4-hydroxy acetophenone Drugs 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 229910014033 C-OH Inorganic materials 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- 229910014570 C—OH Inorganic materials 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010049119 Emotional distress Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001071429 Homo sapiens Metabotropic glutamate receptor 2 Proteins 0.000 description 1
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 description 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000004957 autophagosome Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- AZSZCFSOHXEJQE-UHFFFAOYSA-N dibromodifluoromethane Chemical compound FC(F)(Br)Br AZSZCFSOHXEJQE-UHFFFAOYSA-N 0.000 description 1
- FJBFPHVGVWTDIP-UHFFFAOYSA-N dibromomethane Chemical compound BrCBr FJBFPHVGVWTDIP-UHFFFAOYSA-N 0.000 description 1
- YMWUJEATGCHHMB-DICFDUPASA-N dichloromethane-d2 Chemical compound [2H]C([2H])(Cl)Cl YMWUJEATGCHHMB-DICFDUPASA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009097 homeostatic mechanism Effects 0.000 description 1
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000006674 lysosomal degradation Effects 0.000 description 1
- NIXOIRLDFIPNLJ-UHFFFAOYSA-M magnesium;benzene;bromide Chemical compound [Mg+2].[Br-].C1=CC=[C-]C=C1 NIXOIRLDFIPNLJ-UHFFFAOYSA-M 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- UYCAUPASBSROMS-AWQJXPNKSA-M sodium;2,2,2-trifluoroacetate Chemical group [Na+].[O-][13C](=O)[13C](F)(F)F UYCAUPASBSROMS-AWQJXPNKSA-M 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Definitions
- the invention relates to difluorocyclopropane compounds, methods for their manufacture, and their uses for example as medicaments.
- Autophagy is a highly conserved homeostatic mechanism that involves lysosomal degradation of damaged and unwanted cellular components. It is believed to play an important role in inflammatory diseases such as atherosclerosis and plaque progression, and there is a known correlation between enhancing autophagy and protecting against heart and other common age-related diseases. Autophagy may exert its beneficial effect in atherosclerosis and other diseases by degrading damaged intracellular organelles and thereby preventing oxidative injuries and cellular distresses.
- tamoxifen a potent inducer of autophagy, inhibited atherosclerosis in mice models by suppressing the diet-induced formation of lipid lesions in the aorta by lowering of low-density lipoprotein (LDL) cholesterol.
- LDL low-density lipoprotein
- Tamoxifen (IUPAC name: 2-[4-[(Z)-l,2-diphenylbut-l-enyl]phenoxy]-N,N- dimethylethan-amine) was originally a failed contraceptive that was redeveloped as a breast cancer drug. Tamoxifen has mixed agonist and antagonist activities that are species-, tissue- and cell-specific. In addition to its well-known antitumor properties derived from its anti-estrogenic activity in breast tissue, tamoxifen has also been found to increase the risk of endometrial cancer. The development of more selective autophagy inducers is needed if they are to become medicinally useful in the treatment and/or prevention of diseases such as cardiovascular diseases.
- WO2013/062079 describes l, -difluoro-2,2'-diphenylcycloproprane derivatives as modulators of metabotropic glutamate receptor subtype 2 (mGlu2 receptor) and their uses in the treatment of mental disorders.
- Miyashita et al. 2005; In: “Environmental Fate and Safety Management of Agrochemicals", American Chemical Society, Vol. 899: 159- 166) describes a l, -difluoro-2,2'-diphenylcycloproprane derivative (compound 34 in Fig. 2) as a potential oestrogen receptor inhibitor.
- US5,015,666, US5,658,914 and US5,658,951 describe triarylcyclopropane derivatives and diphenylcyclopropyl analogues stated to be useful as anti-oestrogens and anti-tumour agents. Cheng et al. (2004, Mol Pharmacol 66: 970-977), Singh et al. (1996, Bioorganic Chem 24: 81-94), and Day et al. (1991, J Med Chem 34: 842-851) describe ⁇ , -dichloro diphenylcycloproprane derivatives and their potential medical uses.
- X and Y are phenyl groups, one of which is substituted by an ethoxyamine basic side chain; Ri and R 2 are independently selected from H or a Ci-C 6 alkyl group; and
- X and Y, and the or each Ci-C 6 alkyl group are optionally substituted or further substituted by one or more alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl or alkylamino radicals of 1 to 20 carbon atoms, and/or by one or more fluoro, chloro, bromo, iodo, hydroxy, oxyalkyl, amino, aminoalkyl or aminodialkyl radicals.
- one of the phenyl groups (X or Y) is substituted by the ethoxyamine basic side chain, and consequently the other phenyl group is un- substituted by the ethoxyamine basic side chain.
- Ri and R 2 are as described above; and R-3 is an ethoxyamine basic side chain.
- R4 is an amine group.
- the amine group is other than a morpholine group.
- the amine group may be selected from aminodimethyl, aminodiethyl, pyrrolidin-l-yl and piperidin-l-yl.
- Exemplar compounds within the scope of formulae (I), (II) and (III) include:
- a further exemplar compound is ( ⁇ )-l, l-difluoro-2-(4-(2-(morpholin-l- yl)ethoxy)phenyl)-2-phenylcyclopropane.
- a pharmaceutical composition comprising a compound as described herein and a pharmaceutically or therapeutically acceptable excipient or carrier.
- pharmaceutically or therapeutically acceptable excipient or carrier refers to a solid or liquid filler, diluent or encapsulating substance which does not interfere with the effectiveness or the biological activity of the active ingredients and which is not toxic to the host, which may be either humans or animals, to which it is administered.
- pharmaceutically-acceptable carriers such as those well known in the art may be used.
- Non-limiting examples include sugars, starches, cellulose and its derivatives, malt, gelatin, talc, calcium sulfate, vegetable oils, synthetic oils, polyols, alginic acid, phosphate buffered solutions, emulsifiers, isotonic saline, and pyrogen-free water.
- administration of the medicament may be via oral, subcutaneous, direct intravenous, slow intravenous infusion, continuous intravenous infusion, intravenous or epidural patient controlled analgesia (PCA and PCEA), intramuscular, intrathecal, epidural, intracistemal, intraperitoneal, transdermal, topical, transmucosal, buccal, sublingual, inhalation, intra-atricular, intranasal, rectal or ocular routes.
- the medicament may be formulated in discrete dosage units and can be prepared by any of the methods well known in the art of pharmacy. All suitable pharmaceutical dosage forms are contemplated.
- Administration of the medicament may for example be in the form of oral solutions and suspensions, tablets, capsules, lozenges, effervescent tablets, transmucosal films, suppositories, buccal products, oral mucoretentive products, topical creams, ointments, gels, films and patches, transdermal patches, abuse deterrent and abuse resistant formulations, sterile solutions suspensions and depots for parenteral use, and the like, administered as immediate release, sustained release, delayed release, controlled release, extended release and the like.
- Another aspect of the invention is the use of a compound as defined herein in the manufacture of a medicament for the treatment of a disease.
- the invention also encompasses a method of treating a disease, comprising the step of administering the compound or the pharmaceutical composition as defined herein to a patient in need of same.
- a disease suitable for treatment according to these aspects of the invention is one which is characterised by defective autophagy or which would benefit from modulation of autophagy.
- the disease may be a neurodegenerative disorder (for example, Huntington's disease, Alzheimer's disease or Parkinson's disease), systemic lupus erythematosus (“lupus”), epilepsy, cancer, liver diseases including non-alcoholic fatty liver disease (NAFLD) and a 1 -antitrypsin deficiency (ATD), Niemann-Pick type C ( PC) disease, fibrinogen storage disease (FSB), inclusion body disease (IBD), lysosomal storage disease, muscular dystrophy (for example Duchenne muscular dystrophy or Limb-girdle muscular dystrophy), myopathy (for example myofibrillar myopathy, hereditary myopathy or diabetic cardiomyopathy), or an anti-inflammatory disorder selected from the group consisting of an autoimmune disease (for example multiple sclerosis, rheumatoid arthritis, lupus
- Table 1 Difluorocyclopropanation using Me3SiCF 3 and cz ' s-stilbene as a model substrate.
- Table 1 may seem low in the first instance, but when the method is applied for more reactive alkenes, the conversion is more remarkable. This is shown in Table 2:
- a method of making a compound as defined herein comprising a step of conducting a chemical reaction in a sealed tube in the presence of a reactive compound, a fluorination reagent, a catalyst and solvent, thereby making an intermediate compound for making the compound of the invention as defined herein.
- the intermediate compound may be a difluorocyclopropane compound, for example a diphenyl difluorocyclopropane compound (such as ( ⁇ )-l, l-Difluoro-2-(4-hydroxyphenyl)- 2-phenylcyclo-propane).
- the difluorocyclopropane compound may be further modified such as by substitution, for example by substituting an hydroxyl (-OH) group with an ethoxyamine basic side chain, to form a compound of the invention as defined herein.
- the chemical reaction may be facilitated by heating. Additionally or alternatively, the chemical reaction may be facilitated by microwave radiation.
- the reactive compound may be 4-hydroxy-a- phenylstyrene
- the fluorination reagent may be trifluoromethyltrimethylsilane (TMSCF 3 )
- the catalyst may be Nal
- the solvent may be CH 3 CN.
- the chemical reaction may be conducted at or above 80°C (for example, at not more than 120°C), for example by heating for 2 hours and/or by microwave radiation for 20 min.
- the term "about” refers to an interval around the considered value.
- “about X” means an interval from X minus 10% of X to X plus 10% of X, and preferably an interval from X minus 5% of X to X plus 5% of X.
- the term "comprising” is to be read as meaning both comprising and consisting of. Consequently, where the invention relates to a "pharmaceutical composition comprising as active ingredient" a compound, this terminology is intended to cover both compositions in which other active ingredients may be present and also compositions which consist only of one active ingredient as defined. Unless otherwise defined, all the technical and scientific terms used here have the same meaning as that usually understood by an ordinary specialist in the field to which this invention belongs. Similarly, all the publications, patent applications, all the patents and all other references mentioned here are incorporated by way of reference (where legally permissible).
- Fig. 1 is a histogram showing the effect of compounds ( ⁇ )-l, l-difluoro-2-(4- hydroxyphenyl)-2-phenylcyclopropane ("SKW35”) and ( ⁇ )-l, l-difluoro-2-(4-(2- (dimethylamino)ethoxy)phenyl)-2-phenylcyclopropane (“SKW36”) in a THP-1 autophagy assay (see Example 9);
- Fig. 2 is a histogram showing the effect of compound ( ⁇ )-l, l-difluoro-2-(4-(2- (diethylamino)ethoxy)phenyl)-2-phenylcyclopropane ("SKW46") in a TFIP-1 autophagy assay (see Example 9);
- Fig. 3 is a histogram showing the effect of compound ( ⁇ )-l, l-difluoro-2-(4-(2- (pyrroli din- l-yl)ethoxy)phenyl)-2-phenyl cyclopropane ("SKW48") in a TFIP-1 autophagy assay (see Example 9); and Fig.
- This compound was made by the method of Example 3 using 2-chloro-N,N- diethylethylamine hydrochloride (0.52 g, 3 mmol, 0.75 eq.), l, l-difluoro-2-(4- hydroxyphenyl)-2-phenylcyclopropane (0.98 g, 4 mmol, 1.0 eq.) and anhydrous K 2 C0 3 (1.93 g, 14 mmol, 3.5 eq.) to give 0.71 g (69 %) of the title compound as an oil.
- This compound was made by the method of Example 3 using l-(2- chloroethyl)pyrrolidine hydrochloride (0.51 g, 3 mmol, 0.75 eq.), l, l-difluoro-2-(4- hydroxyphenyl)-2-phenylcyclopropane (0.98 g, 4 mmol, 1.0 eq.) and anhydrous K 2 C0 3 (1.93 g, 14 mmol, 3.5 eq.) to give 0.78 g (76 %) of the title compound as an oil which solidified upon stored at 0°C.
- This compound was made by the method of Example 3 using l-(2-chloroethyl)piperidine hydrochloride (0.55 g, 3 mmol, 0.75 eq.), l, l-difluoro-2-(4-hydroxyphenyl)-2- phenylcyclopropane (0.98 g, 4 mmol, 1.0 eq.) and anhydrous K 2 C0 3 (1.93 g, 14 mmol, 3.5 eq.) to give 0.70 g (65 %) of the title compound as an oil which solidified upon stored at 0°C.
- the crude oil was purified using silica chromatography (silica gel, acetone: petroleum ether, 20: 80) before 2 ml of 3N HC1 solution was added and the solvent was reduced in vacuo.
- the solid was recrystallised in acetone to give 0.52 g (44 %) of the title compound as a white solid.
- Example 8 Effect of difluorocyclopropane compounds in an in vitro autophagy assay
- Human THP-1 cells a myelo-monocytic cell line, were plated into 24 well plates (8 x 10 5 cells/ml with 500 ⁇ of media/well) and differentiated into macrophages for 24 hr by incubating with 200 nM phorbol-12-myristate (PMA) at 37°C in a humidified atmosphere containing 5% C0 2 .
- PMA phorbol-12-myristate
- TFIP-1 cells were washed with fresh media and treated in triplicate with vehicle (0.8% DMSO in RPMI-1640 media), 3 ⁇ tamoxifen (TMX, positive control) or different difluorocyclopropane compounds (final concentration 10 ⁇ ) for 18 hr (overnight) in a 37°C incubator in a final volume of 500 ⁇ 1.
- TMX 3 ⁇ tamoxifen
- difluorocyclopropane compounds final concentration 10 ⁇
- the cells were washed and removed from each well using trypsin/EDTA and placed in to glass tubes before being processed for the detection of lysosomal/autophagic vacuoles using a commercially available autophagy kit (Abeam, ab 139484).
- the Abeam kit uses a proprietary dye, which is a cationic amphiphilic tracer, which selectively labels autophagic vacuoles in the perinuclear region of the cell.
- the procedure of staining was carried out per the manufacturer's instructions. Briefly, the cells were centrifuged (100 x g for 5 minutes at RT), washed in fresh media (RPMI phenol red free/5% FBS) and resuspended in 500 ⁇ media containing the Cyto-ID green staining dye provided in the kit (final concentration IX) and were incubated for 30 minutes at 37°C in the dark. Finally, cells were washed and fixed in 2% PFA.
- the cells were analysed in the FITC channel on a flow cytometer (BD Facs Calibur) with at least 15,000 events collected per sample.
- the cell population was gated in the forward and side scatter channels and the median fluorescence intensity (MFI) in the FITC channel was reported for each sample.
- MFI median fluorescence intensity
- TMX Tamoxifen
- SKW35 has no amine side chain and does not stimulate autophagy (see Fig. 1).
- all compounds tested containing an amine side chain include SKW36, SKW46, SKW48 and SKW49) stimulate autophagy in THP-1 cells, which demonstrates the presence of an amine side chain is important for induction of autophagy (see Figs 1- 4).
- SKW36, SKW46, SKW48 and SKW49 induce an increase of lysosomal/autophagic vacuoles in THP-1 cells, as measured by an increase in median fluorescence staining by flow cytometry techniques, compared to cells treated with vehicle (see Figs 1 - 4).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to difluorocyclopropane compounds, methods for their manufacture, and their uses for example as medicaments. According to one aspect, there is provided a compound of general formula (I): wherein X and Y are phenyl groups, one of which is substituted by an ethoxyamine basic side chain; R1 and R2 are independently selected from H or a C1-C6 alkyl group; and wherein one or each of X and Y, and the or each C1-C6 alkyl group, are optionally substituted or further substituted by one or more alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl or alkylamino radicals of 1 to 20 carbon atoms, and/or by one or more fluoro, chloro, bromo, iodo, hydroxy, oxyalkyl, amino, aminoalkyloraminodialkyl radicals.
Description
Compounds
The invention relates to difluorocyclopropane compounds, methods for their manufacture, and their uses for example as medicaments.
Autophagy is a highly conserved homeostatic mechanism that involves lysosomal degradation of damaged and unwanted cellular components. It is believed to play an important role in inflammatory diseases such as atherosclerosis and plaque progression, and there is a known correlation between enhancing autophagy and protecting against heart and other common age-related diseases. Autophagy may exert its beneficial effect in atherosclerosis and other diseases by degrading damaged intracellular organelles and thereby preventing oxidative injuries and cellular distresses.
Grainger et al. (1995, Nature Medicine 1 : 1067-1073) and Reckless et al. (1997, Circulation 95: 1542-1548) have demonstrated that tamoxifen, a potent inducer of autophagy, inhibited atherosclerosis in mice models by suppressing the diet-induced formation of lipid lesions in the aorta by lowering of low-density lipoprotein (LDL) cholesterol.
Tamoxifen (prior art)
Tamoxifen (IUPAC name: 2-[4-[(Z)-l,2-diphenylbut-l-enyl]phenoxy]-N,N- dimethylethan-amine) was originally a failed contraceptive that was redeveloped as a breast cancer drug. Tamoxifen has mixed agonist and antagonist activities that are species-, tissue- and cell-specific. In addition to its well-known antitumor properties derived from its anti-estrogenic activity in breast tissue, tamoxifen has also been found to
increase the risk of endometrial cancer. The development of more selective autophagy inducers is needed if they are to become medicinally useful in the treatment and/or prevention of diseases such as cardiovascular diseases. WO2013/062079 describes l, -difluoro-2,2'-diphenylcycloproprane derivatives as modulators of metabotropic glutamate receptor subtype 2 (mGlu2 receptor) and their uses in the treatment of mental disorders. Miyashita et al. (2005; In: "Environmental Fate and Safety Management of Agrochemicals", American Chemical Society, Vol. 899: 159- 166) describes a l, -difluoro-2,2'-diphenylcycloproprane derivative (compound 34 in Fig. 2) as a potential oestrogen receptor inhibitor. US5,015,666, US5,658,914 and US5,658,951 describe triarylcyclopropane derivatives and diphenylcyclopropyl analogues stated to be useful as anti-oestrogens and anti-tumour agents. Cheng et al. (2004, Mol Pharmacol 66: 970-977), Singh et al. (1996, Bioorganic Chem 24: 81-94), and Day et al. (1991, J Med Chem 34: 842-851) describe Ι, -dichloro diphenylcycloproprane derivatives and their potential medical uses.
According to a first aspect of the present invention, there is provided a compound of general formula (I):
X and Y are phenyl groups, one of which is substituted by an ethoxyamine basic side chain;
Ri and R2 are independently selected from H or a Ci-C6 alkyl group; and
wherein one or each of X and Y, and the or each Ci-C6 alkyl group, are optionally substituted or further substituted by one or more alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl or alkylamino radicals of 1 to 20 carbon atoms, and/or by one or more fluoro, chloro, bromo, iodo, hydroxy, oxyalkyl, amino, aminoalkyl or aminodialkyl radicals.
According to the invention, one of the phenyl groups (X or Y) is substituted by the ethoxyamine basic side chain, and consequently the other phenyl group is un- substituted by the ethoxyamine basic side chain.
Initially, we developed a range of dichlorocyclopropane analogues of tamoxifen (data not shown). However, we found these to be unstable, and thus turned our attention to difluorocyclopropane analogues. Known methods for generating relevant difluorocyclopropane compounds were limited. We describe herein methods to improve the efficiency of generating such compounds. Novel compounds described herein are shown using in vitro data to be effective autophagy inducers (see below).
The compound described above may have a structure of general formula (II):
wherein Ri and R2 are as described above; and
R-3 is an ethoxyamine basic side chain.
Alternatively, the compound described above may have a structure of general formula (III):
wherein R4 is an amine group. Optionally, the amine group is other than a morpholine group. For example, the amine group may be selected from aminodimethyl, aminodiethyl, pyrrolidin-l-yl and piperidin-l-yl.
Exemplar compounds within the scope of formulae (I), (II) and (III) include:
(±)- 1 , 1 -difluoro-2-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenyl cyclopropane;
(±)- 1 , 1 -difluoro-2-(4-(2-(diethylamino)ethoxy)phenyl)-2-phenyl cyclopropane;
(±)- 1 , 1 -difluoro-2-(4-(2-(pyrrolidin- 1 -yl)ethoxy)phenyl)-2-phenyl cyclopropane; and (±)- 1 , 1 -difluoro-2-(4-(2-(piperidin- 1 -yl)ethoxy)phenyl)-2-phenyl cyclopropane.
A further exemplar compound is (±)-l, l-difluoro-2-(4-(2-(morpholin-l- yl)ethoxy)phenyl)-2-phenylcyclopropane.
According to a further aspect of the invention, there is a provided a pharmaceutical composition comprising a compound as described herein and a pharmaceutically or therapeutically acceptable excipient or carrier.
The term "pharmaceutically or therapeutically acceptable excipient or carrier" refers to a solid or liquid filler, diluent or encapsulating substance which does not interfere with the effectiveness or the biological activity of the active ingredients and which is not toxic to the host, which may be either humans or animals, to which it is administered. Depending upon the particular route of administration, a variety of pharmaceutically-acceptable carriers such as those well known in the art may be used. Non-limiting examples include sugars, starches, cellulose and its derivatives, malt, gelatin, talc, calcium sulfate, vegetable oils, synthetic oils, polyols, alginic acid, phosphate buffered solutions, emulsifiers, isotonic saline, and pyrogen-free water.
All suitable modes of administration are contemplated according to the invention. For example, administration of the medicament may be via oral, subcutaneous, direct intravenous, slow intravenous infusion, continuous intravenous infusion, intravenous or epidural patient controlled analgesia (PCA and PCEA), intramuscular, intrathecal, epidural, intracistemal, intraperitoneal, transdermal, topical, transmucosal, buccal, sublingual, inhalation, intra-atricular, intranasal, rectal or ocular routes. The medicament may be formulated in discrete dosage units and can be prepared by any of the methods well known in the art of pharmacy. All suitable pharmaceutical dosage forms are contemplated. Administration of the medicament may for example be in the form of oral solutions and suspensions, tablets, capsules, lozenges, effervescent tablets, transmucosal films, suppositories, buccal products, oral mucoretentive products, topical creams, ointments, gels, films and patches, transdermal patches, abuse deterrent and abuse resistant formulations, sterile solutions suspensions and depots for parenteral use, and the like, administered as immediate release, sustained release, delayed release, controlled release, extended release and the like.
Another aspect of the invention is the use of a compound as defined herein in the manufacture of a medicament for the treatment of a disease.
Further provided is a compound as defined herein for use in the treatment of a disease.
The invention also encompasses a method of treating a disease, comprising the step of administering the compound or the pharmaceutical composition as defined herein to a patient in need of same.
A disease suitable for treatment according to these aspects of the invention is one which is characterised by defective autophagy or which would benefit from modulation of autophagy. The disease may be a neurodegenerative disorder (for example, Huntington's disease, Alzheimer's disease or Parkinson's disease), systemic lupus erythematosus ("lupus"), epilepsy, cancer, liver diseases including non-alcoholic fatty liver disease (NAFLD) and a 1 -antitrypsin deficiency (ATD), Niemann-Pick type C ( PC) disease, fibrinogen storage disease (FSB), inclusion body disease (IBD), lysosomal storage disease, muscular dystrophy (for example Duchenne muscular dystrophy or Limb-girdle muscular dystrophy), myopathy (for example myofibrillar myopathy, hereditary myopathy or diabetic cardiomyopathy), or an anti-inflammatory disorder selected from the group consisting of an autoimmune disease (for example multiple sclerosis, rheumatoid arthritis, lupus, irritable bowel syndrome, Crohn's disease), vascular disorders (including stroke, coronary artery diseases, myocardial infarction, unstable angina pectoris, atherosclerosis or vasculitis [such as Behcet's syndrome, giant cell arteritis, polymyalgia rheumatica, Wegener's granulomatosis, Churg- Strauss syndrome vasculitis, Henoch- Schonlein purpura or Kawasaki disease]), viral infection or replication (for example infections due to or replication of viruses including pox virus, herpes virus such as Herpesvirus samiri, cytomegalovirus [CMV], hepatitis viruses or lentiviruses [including HIV]), asthma and related respiratory disorders such as allergic rhinitis and COPD, osteoporosis (low bone mineral density), tumour growth, organ transplant rejection and/or delayed graft or organ function (for example in renal transplant patients), a disorder characterised by an elevated T F-α level, psoriasis, skin wounds and other fibrotic disorders including hypertrophic scarring (keloid formation), adhesion formations following general or gynaecological surgery, lung fibrosis, liver fibrosis (including alcoholic liver disease) or kidney fibrosis, whether idiopathic or as a consequence of an underlying disease such as diabetes (diabetic nephropathy), disorders caused by intracellular parasites such as malaria or tuberculosis, neuropathic pain (such as post-
operative phantom limb pain or postherpetic neuralgia), allergies, ALS, antigen induced recall response and immune response suppression.
Numerous methods have been used in the prior art for the synthesis of difluorocyclopropyl stilbene analogues including reaction of CH2Br2 and CBr2F2 with a strong aqueous base in the presence of tetrabutylammonium hydrogensulphate as a PTC catalyst, thermal decomposition of sodium trifluoroacetate, chlorodifluoroacetate and bromodifluoroacetate, and NaF induced thermal decomposition of TFDA. They all failed to affect the difluorocyclopropanation on the relatively nucleophilic-poor stilbenes.
We found previously that the difluorocyclopropanation of stilbenes with Me3SiCF3 using microwave irradiation was more effective than known reactions (see Wong & Fox, 2012, 20th International Symposium of Fluorine Chemistry, Kyoto, 22-27 July 2012). For example, the stilbenes transformed into difluorocyclopropanes after heating the reaction mixture in a sealed microwave tube for just 20 minutes at 80°C (Scheme 1, below), at a conversion rate of - 22%.
~ 22%
conversion
Scheme 1
Through optimisation of various parameters, conversion of up to 30 % was achieved
(see Scheme 2 below, where "temp" refers to microwave heating). Replacement of Nal with a different salt: NaF, NaCl, NaBr, KF, KCl, KBr, KI and CsF resulted in no or only trace amount of product being formed. When TUF, toluene, diglyme, DMF and DMSO were used as solvents instead of CH3CN, only trace amount of difluorocyclopropanes were detected. If reaction temperature was below 80°C, little difluorocyclopropane was formed in the 20 minutes timescale, indicating that a sustainable high temperature (>
80°C) is required to overcome the energy barrier for the addition of :CF2 to the olefins. Conversion of trans-stilbe to the desired trans- difluorocyclopropane increased with increasing reaction temperature, but only up to ~ 30% at 130°C. At 140°C, isomerisation of tram'-difluorocyclopropane to czs-difluorocyclopropane was observed in a small percentage (~ 2%) of compounds. With cz's-stilbene, the situation is a little bit more complicated. Table 1 provides a summary of selected reactions when cz's-stilbene was used as the model substrate.
(±) (±) B C D
Scheme 2
Microwave % of crude reaction mixture
Catalyst heating
Entry Solvent
(equiv.) conditions: A B C D
°C Mins
1 THF Nal (2.5) 80 20 - 99 Trace 0 0
2 Toluene Nal (2.5) 80 20 - 99 Trace 0 0
3 Diglyme Nal (2.5) 80 20 - 99 Trace 0 0
4 CH3CN Nal (2.5) 60 20 - 99 Trace 0 0
5 CH3CN Nal (2.5) 80 20 - 36 - 41 - 22 - 1
6 CH3CN Nal (2.5) 100 20 - 34 - 50 - 15 - 1
7 CH3CN Nal (2.5) 120 20 - 26 - 57 - 1 - 16
8 CH3CN Nal (2.5) 80 10 - 63 - 20 - 17 0
9 CH3CN KF (2.5) 80 20 - 99 Trace 0 0
10 CH3CN CsF (0.2) 60 20 - 99 Trace Trace 0
11 THF CsF (0.2) 60 20 - 99 Trace Trace 0
12 Toluene CsF (0.2) 60 20 - 95 Trace - 5 0
13 Toluene CsF (0.5) 60 20 - 98 Trace - 2 0
Table 1 : Difluorocyclopropanation using Me3SiCF3 and cz's-stilbene as a model substrate.
At 80 °C, about 22% of cz's-stilbene was converted to difluorocyclopropane, while a significant amount of starting material (~ 41%>) was isomerized into the tra/w-stilbene which was also accompanied by the formation of trans- difluorocyclopropane (~ 1 %>) (see Entry 5). Interestingly, at temperature > 120°C, tram'-difluorocyclopropane (16 %>) was detected as the major cyclopropane product (see Entry 7). The cis- and trans- isomerisation was increased from 41%> to 57%>, whereas the overall formation of difluorocyclopropane was reduced from 23%> to 17%>.
Difluorocyclopropanation using microwave radiation provides a fast and convenient way to form difluorocyclopropanes in just 20 minutes. The conversion shown in Entry 5 of
Table 1 may seem low in the first instance, but when the method is applied for more reactive alkenes, the conversion is more remarkable. This is shown in Table 2:
Table 2: Conversion of more reactive olefins using microwave radiation.
We have found the above and other prior art methods for producing dichlorocyclopropanes, using for example the relatively nucleophilic-poor stilbenes as starting material, to be lacking. The present disclosure provides improved methods. In another aspect of the present invention, there is provided a method of making a compound as defined herein, wherein the method comprises a step of conducting a chemical reaction in a sealed tube in the presence of a reactive compound, a fluorination reagent, a catalyst and solvent, thereby making an intermediate compound for making the compound of the invention as defined herein.
The intermediate compound may be a difluorocyclopropane compound, for example a diphenyl difluorocyclopropane compound (such as (±)-l, l-Difluoro-2-(4-hydroxyphenyl)- 2-phenylcyclo-propane). The difluorocyclopropane compound may be further modified such as by substitution, for example by substituting an hydroxyl (-OH) group with an ethoxyamine basic side chain, to form a compound of the invention as defined herein.
The chemical reaction may be facilitated by heating.
Additionally or alternatively, the chemical reaction may be facilitated by microwave radiation. In the method of the invention, the reactive compound may be 4-hydroxy-a- phenylstyrene, the fluorination reagent may be trifluoromethyltrimethylsilane (TMSCF3), the catalyst may be Nal and the solvent may be CH3CN. The chemical reaction may be conducted at or above 80°C (for example, at not more than 120°C), for example by heating for 2 hours and/or by microwave radiation for 20 min.
The very high conversion obtained with other alkenes further provides evidence that stilbenes are unreactive toward difluorocarbene. The improvements in the methods noted above are therefore significant. As used herein, the term "about" refers to an interval around the considered value. As used in this patent application, "about X" means an interval from X minus 10% of X to X plus 10% of X, and preferably an interval from X minus 5% of X to X plus 5% of X.
The use of a numerical range in this description is intended unambiguously to include within the scope of the invention all individual integers within the range and all the combinations of upper and lower limit numbers within the broadest scope of the given range.
As used herein, the term "comprising" is to be read as meaning both comprising and consisting of. Consequently, where the invention relates to a "pharmaceutical composition comprising as active ingredient" a compound, this terminology is intended to cover both compositions in which other active ingredients may be present and also compositions which consist only of one active ingredient as defined. Unless otherwise defined, all the technical and scientific terms used here have the same meaning as that usually understood by an ordinary specialist in the field to which this invention belongs. Similarly, all the publications, patent applications, all the patents and
all other references mentioned here are incorporated by way of reference (where legally permissible).
Particular non-limiting examples of the present invention will now be described with reference to the following drawings, in which:
Fig. 1 is a histogram showing the effect of compounds (±)-l, l-difluoro-2-(4- hydroxyphenyl)-2-phenylcyclopropane ("SKW35") and (±)-l, l-difluoro-2-(4-(2- (dimethylamino)ethoxy)phenyl)-2-phenylcyclopropane ("SKW36") in a THP-1 autophagy assay (see Example 9);
Fig. 2 is a histogram showing the effect of compound (±)-l, l-difluoro-2-(4-(2- (diethylamino)ethoxy)phenyl)-2-phenylcyclopropane ("SKW46") in a TFIP-1 autophagy assay (see Example 9);
Fig. 3 is a histogram showing the effect of compound (±)-l, l-difluoro-2-(4-(2- (pyrroli din- l-yl)ethoxy)phenyl)-2-phenyl cyclopropane ("SKW48") in a TFIP-1 autophagy assay (see Example 9); and Fig. 4 is a histogram showing the effect of compounds (±)-l, l-difluoro-2-(4-(2- (morpholin-l-yl)ethoxy)phenyl)-2-phenyl cyclopropane ("SKW47") and (±)-l, l- difluoro-2-(4-(2-(piperi din- l-yl)ethoxy)phenyl)-2-phenyl cyclopropane ("SKW49") in a TFIP-1 autophagy assay (see Example 9).
Experimental Example 1 (Reference): 4-Hydroxy-a-phenylstyrene
This compound was prepared according to the method of Fischer & Wan (1999, J. Am. Chem. Soc. 121 : 4555-4562). A solution of 4-hydroxyacetophenone (2.72 g, 20 mmol, 1.0 eq.) in THF (150 ml) was added dropwise to PhMgBr [62 mmol, 3.1 eq., prepared by adding PhBr (6.53 ml, 62 mmol, 3.1 eq.) in THF (30 ml) to Mg turning (1.60 g, 66 mmol, 3.3 eq.) in THF (30 ml) with a few grains of I2 crystals] cooled on in ice bath. After the reaction was stirred for 30 minutes and the reaction was completed as monitored by TLC. The reaction was quenched by water (100 ml) and the organic material was exacted by diethyl ether (3 x 50 ml), dried over MgS04 to give the tertiary alcohol. A little of ^-toluenesulfonic acid were added to the tertiary alcohol in toluene (100 ml) and the resulting solution was heated at reflux for 1 hour before the solvent was reduced in vacuo. Water was added and the organic material was extracted with diethyl ether (3 x 50 ml), dried over MgS04 to afford an oil. The crude oil was purified by standard silica chromatography to give the title compound (3.49 g, 89 %) as a light yellowish oil. ¾ NMR (300 MHz, CDC13): δ 7.30-7.21 (5H, m, Ar-H), 7.17-7.11 (2H, m, HOCCHCH), 6.75-6.67 (2H, m, HOCCH), 6.20-5.80 (1H, m, OH), 5.35 (1H, d, J = 1.2, CH2), 5.31 (1H, d, J = 1.2, CH2); 13C NMR (75 MHz, CDC13) δ 155.78 (C-OH), 149.77, 142.09, 134.30 (ipso Ar-C and CCH2) 129.90, 128.62, 128.43, 127.96, 115.35 (Ar-C), 113.22 (C¾)- These data are consistent with that previously reported (see Ojha & Prabhu, 2012, J. Organic Chem. 77: 11027-11033).
Example 2 ( Preparation of Intermediate): (±)- 1 , l-Difluoro-2-(4-h droxyphenyl)-2- phenylcyclo-propane ("SKW35")
To a 35 ml pressure tube containing 4-hydroxy-a-phenylstyrene (1.05 g, 5 mmol, 1.0 eq.) in CH3CN (20 ml) was added Nal (3.75 g, 25 mmol, 5.0 eq.) and TMSCF3 (3.7 ml, 25 mmol, 5.0 eq.) and the pressure tube was securely sealed. The resulting mixture was heated at 80° C for 2 hours. After that, the mixture was filtered and the solid washed with CH3CN (2 x 10 ml). The filtrate and washings were reduced in vacuo and re- dissolved in methanol (15 ml), followed by addition of N-bromosuccinimide (0.18 g, 1 mmol, 0.2 eq.). The mixture was then stirred at room temperature for 2 hours. After that, the methanol was removed in vacuo and the crude was purified using standard silica chromatography to give 0.82 g (67 %) of the title compound as an oil which solidified to a low-melting waxy solid on standing. ¾ NMR (300 MHz, CDC13): δ 7.40-7.18 (7H, m, Ar-H), 6.77-6.72 (2H, m, HOCCH), 5.26 (1H, br s, OH), 2.10-1.94 (2H, m, CH2); 19F NMR (282 MHz, CDC13) δ -130.62 - -130.74 (m). ¾ NMR spectrometric data are consistent with those reported in WO 2013062079 Al (no synthetic method given). Example 3: (±)-l,l-Difluoro-2-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenylcyclo- propane ("SKW36")
A mixture of 2-chloro-N,N-dimethylethylamine hydrochloride (0.43 g, 3 mmol, 0.75 eq.), l, l-difluoro-2-(4-hydroxyphenyl)-2-phenyl cyclopropane (0.98 g, 4 mmol, 1.0 eq.) and anhydrous K2C03 (1.93 g, 14 mmol, 3.5 eq.) in acetone (50 ml ) was heated at reflux overnight. After cooling to ambient temperature, the solid was filtered and the filtrate was reduced in vacuo to give a crude product. The crude was purified using silica chromatography (silica gel, acetone: petroleum ether, 20: 80) to give 0.74 g (77 %) of the title compound as an oil which solidified upon stored at 0°C. ¾ NMR (300 MHz, CDCI3) δ 7.23 - 6.99 (7H, m, Ar-H), 6.71 - 6.64 (2H, m, CH2OCCH), 3.83 (2H, t, J = 6, OG¾CH2), 2.50 (2H, t, J = 6, OCH2G¾), 2.12 (6H, s, N(G¾)2), 1.91 - 1.78 (2H, m,CF2G¾). 19F NMR (282 MHz, CDC13) δ -130.55- -130.76 (m).HRMS (ESI): m/z for (Ci9H22F2NO) [M+H] calculated 318.1669 found 318.1668.
Example 4: (±)-l,l-Difl oro-2-(4-(2-(diethylamino)ethoxy)phenyl)-2-phenylcyclo- propane ("SKW46")
This compound was made by the method of Example 3 using 2-chloro-N,N- diethylethylamine hydrochloride (0.52 g, 3 mmol, 0.75 eq.), l, l-difluoro-2-(4- hydroxyphenyl)-2-phenylcyclopropane (0.98 g, 4 mmol, 1.0 eq.) and anhydrous K2C03 (1.93 g, 14 mmol, 3.5 eq.) to give 0.71 g (69 %) of the title compound as an oil. ¾ NMR (300 MHz, CDC13) δ 7.52 - 7.00 (7H, m, Ar-H), 6.81 (2Η, m, CH2OCCH), 4.13 (2Η, t, J = 5.5, OG¾CH2), 3.01 (2H, t, J = 5.5 OCH2CH2), 2.79 (4Η, q, J = 7.0, CH2CH3), 2.05 - 1.87 (2H, m, CF2G¾), 1.14 (6H, t, J = 7.0, CH2CH5). 19F NMR (282 MHz, CDCI3) δ -128.98 - -132.05 (m). HRMS (ESI): m/z for (C2iH26F2NO) [M+H] calculated 346.1982 found 346.1976.
Example 5: (±)- 1 , l-Difluoro-2-(4-(2-(pyrrolidin- l-yl)ethoxy)phenyl)-2-phenylcyclo- propane ("SKW48")
This compound was made by the method of Example 3 using l-(2- chloroethyl)pyrrolidine hydrochloride (0.51 g, 3 mmol, 0.75 eq.), l, l-difluoro-2-(4- hydroxyphenyl)-2-phenylcyclopropane (0.98 g, 4 mmol, 1.0 eq.) and anhydrous K2C03 (1.93 g, 14 mmol, 3.5 eq.) to give 0.78 g (76 %) of the title compound as an oil which solidified upon stored at 0°C. ¾ NMR (300 MHz, CDC13) δ 7.38 - 7.1 1 (7H, m, Ar-H), 6.85 - 6.76 (2H, m, CH2OCCH), 4.04 (2H, t, J = 6.0, OG¾CH2), 2.84 (2H, t, J = 6.0 Hz, OCH2G¾), 2.67 - 2.45 (4H, m, N(CH2)2), 2.04 - 1.90 (2H, m, CF2G¾), 1.82 - 1.68 (4H, m, NCH2G¾G¾). 19F NMR (282 MHz, CDC13) δ -129.46 - -130.61 (m). HRMS (ESI): m/z for (C2iH24F2NO) [M+H] calculated 344.1826 found 344.1819.
Example 6: (±)-l,l-Difluoro-2-(4-(2-(piperidin-l-yl)ethoxy)phenyl)-2-phenylcyclo- propane ("SKW49")
This compound was made by the method of Example 3 using l-(2-chloroethyl)piperidine hydrochloride (0.55 g, 3 mmol, 0.75 eq.), l, l-difluoro-2-(4-hydroxyphenyl)-2- phenylcyclopropane (0.98 g, 4 mmol, 1.0 eq.) and anhydrous K2C03 (1.93 g, 14 mmol, 3.5 eq.) to give 0.70 g (65 %) of the title compound as an oil which solidified upon stored at 0°C. ¾ NMR (300 MHz, CDC13) δ 7.42 - 7.08 (7H, m, Ar-H), 6.88 - 6.71 (2Η, m, CH2OCCH), 4.00 (2Η, t, J = 6.0, OG¾CH2), 2.69 (2H, t, J = 6.0 Hz, OCH2CH2), 2.51 - 2.31 (4Η, m, NG¾CH2CH2), 2.06 - 1.86 (2H, m, CF2G¾), 1.62 - 1.47 (4H, NCH2G¾CH2), 1.44 - 1.30 (2H, m, NCH2CH2G¾). 19F NMR (282 MHz,
CDCI3) δ -130.05 - -13 1.16 (m). HRMS (ESI): m/z for (C22H26F2NO) [M+H] calculated 358.1982 found 358.1982.
Example 7 (Reference): (±)-l,l-Difl oro-2-(4-(2-(morpholin-l-yl)ethoxy)phenyl)-2- phenylcyclopropane ("SKW47")
■Θ
HCI
A mixture of 4-(2-Chloroethyl)morpholine hydrochloride (0.55 g, 3 mmol, 0.75 eq.), l, l-difluoro-2-(4-hydroxyphenyl)-2-phenyl cyclopropane (0.98 g, 4 mmol, 1.0 eq.) and anhydrous K2C03 (1.93 g, 14 mmol, 3.5 eq.) in acetone (50 ml ) was heated at reflux overnight. After cooling to ambient temperature, the solid was filtered and the filtrate was reduced in vacuo to give a crude oil. The crude oil was purified using silica chromatography (silica gel, acetone: petroleum ether, 20: 80) before 2 ml of 3N HC1 solution was added and the solvent was reduced in vacuo. The solid was recrystallised in acetone to give 0.52 g (44 %) of the title compound as a white solid. ¾ MR (400 MHz, CD2C12) δ 7.48 - 7.04 (7H, m, Ar-H ), 6.82 (2H, m, CH2OCCH), 4.47 - 4.42 (2H, m, ArOG¾CH2), 4.26 - 3.70 (4H, m, N(CH2G¾)20), 3.57 - 3.16 (4H, m, ArOCH2G¾ and N(G¾CH2)20), 2.98 (2H, br s, N(G¾CH2)20), 1.98 (2H, dq, J = 15.5, 8.0, G¾CF2). HRMS (ESI): m/z for (C2iH24F2N02) [M-Cl] calculated 360.1775 found 360.1770.
Example 8: Effect of difluorocyclopropane compounds in an in vitro autophagy assay
Methods
Human THP-1 cells, a myelo-monocytic cell line, were plated into 24 well plates (8 x 105 cells/ml with 500 μΐ of media/well) and differentiated into macrophages for 24 hr by
incubating with 200 nM phorbol-12-myristate (PMA) at 37°C in a humidified atmosphere containing 5% C02. Following differentiation TFIP-1 cells were washed with fresh media and treated in triplicate with vehicle (0.8% DMSO in RPMI-1640 media), 3 μΜ tamoxifen (TMX, positive control) or different difluorocyclopropane compounds (final concentration 10μΜ) for 18 hr (overnight) in a 37°C incubator in a final volume of 500μ1. At the end of the incubation step the cells were washed and removed from each well using trypsin/EDTA and placed in to glass tubes before being processed for the detection of lysosomal/autophagic vacuoles using a commercially available autophagy kit (Abeam, ab 139484).
The Abeam kit uses a proprietary dye, which is a cationic amphiphilic tracer, which selectively labels autophagic vacuoles in the perinuclear region of the cell. The procedure of staining was carried out per the manufacturer's instructions. Briefly, the cells were centrifuged (100 x g for 5 minutes at RT), washed in fresh media (RPMI phenol red free/5% FBS) and resuspended in 500 μΐ media containing the Cyto-ID green staining dye provided in the kit (final concentration IX) and were incubated for 30 minutes at 37°C in the dark. Finally, cells were washed and fixed in 2% PFA. The cells were analysed in the FITC channel on a flow cytometer (BD Facs Calibur) with at least 15,000 events collected per sample. The cell population was gated in the forward and side scatter channels and the median fluorescence intensity (MFI) in the FITC channel was reported for each sample.
The following compounds were tested: 1. Tamoxifen ("TMX"; positive control)
2. (±)-l, l-Difluoro-2-(4-hydroxyphenyl)-2-phenylcyclopropane ("SKW35"; see Example 2)
3. (±)- 1 , 1 -Difluoro-2-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenyl cyclopropane ("SKW36"; see Example 3)
4. (±)-l, l-Difluoro-2-(4-(2-(diethylamino)ethoxy)phenyl)-2-phenyl cyclopropane
("SKW46"; see Example 4)
5. (±)- 1 , 1 -Difluoro-2-(4-(2-(pyrrolidin- 1 -yl)ethoxy)phenyl)-2-phenyl cyclopropane ("SKW48"; see Example 5)
6. (±)- 1 , 1 -Difluoro-2-(4-(2-(piperidin- 1 -yl)ethoxy)phenyl)-2-phenyl cyclopropane ("SKW49"; see Example 6)
7. (±)- 1 , 1 -Difluoro-2-(4-(2-(morpholin- 1 -yl)ethoxy)phenyl)-2-phenyl cyclopropane
("SKW47"; see Example 7).
Results
We have tested a number of difluorocyclopropane compounds as well as tamoxifen (positive control) in an in vitro autophagy assay using THP-1 macrophages. The extent of autophagy was measured using a fluorescent dye, which selectively labels autophagosomes. All experimental compounds were tested at 10 μΜ. Tamoxifen ("TMX") was used as a positive control for all in vitro autophagy experiments. It was tested at 3 μΜ as at higher concentrations the compound has a toxic effect on the cells.
SKW35 has no amine side chain and does not stimulate autophagy (see Fig. 1). In contrast, all compounds tested containing an amine side chain (including SKW36, SKW46, SKW48 and SKW49) stimulate autophagy in THP-1 cells, which demonstrates the presence of an amine side chain is important for induction of autophagy (see Figs 1- 4). In all cases, SKW36, SKW46, SKW48 and SKW49 induce an increase of lysosomal/autophagic vacuoles in THP-1 cells, as measured by an increase in median fluorescence staining by flow cytometry techniques, compared to cells treated with vehicle (see Figs 1 - 4). The presence of the oxygen in the morpholine group of SKW47 abolishes the induction of autophagy in THP-1 cells compared to SKW49 (contains a piperidine group, see Fig. 4). Later testing of the hydrochloride salt of SKW49 showed this had no effect on induction of autophagy, confirming that it is the morpholine group in SKW47 which is responsible for the lack of autophagic activity in THP-1 cells.
Conclusions
Several of the difluorocyclopropane compounds tested here can induce autophagy in human THP-1 cells. We have found the presence of an amine group is important for this activity, but where this amine is part of a morpholine group the activity is abolished by the presence of the oxygen.
Although the present invention has been described with reference to preferred or exemplary embodiments, those skilled in the art will recognize that various modifications and variations to the same can be accomplished without departing from the spirit and scope of the present invention and that such modifications are clearly contemplated herein. No limitation with respect to the specific embodiments disclosed herein and set forth in the appended claims is intended nor should any be inferred. All documents cited herein are incorporated by reference in their entirety.
Claims
1. A compound of general formula (I):
X and Y are phenyl groups, one of which is substituted by an ethoxyamine basic side chain;
Ri and R2 are independently selected from H or a Ci-C6 alkyl group; and
wherein one or each of X and Y, and the or each Ci-C6 alkyl group, are optionally substituted or further substituted by one or more alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl or alkylamino radicals of 1 to 20 carbon atoms, and/or by one or more fluoro, chloro, bromo, iodo, hydroxy, oxy alkyl, amino, aminoalkyl or aminodialkyl radicals.
2. The compound according to claim 1, having a structure of general formula (II):
(Π) wherein Ri and R2 are as described above; and
R3 is an ethoxyamine basic side chain.
3. The compound according to either of claim 1 or claim 2, having a structure of general formula (III):
4. The compound according to claim 3, wherein the amine group is selected from aminodimethyl, aminodi ethyl, pyrrolidin-l-yl and piperidin-l-yl.
5. The compound according to any preceding claim, wherein the compound is selected from:
(±)- 1 , 1 -difluoro-2-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenyl cyclopropane;
(±)- 1 , 1 -difluoro-2-(4-(2-(diethylamino)ethoxy)phenyl)-2-phenyl cyclopropane;
(±)- 1 , 1 -difluoro-2-(4-(2-(pyrrolidin- 1 -yl)ethoxy)phenyl)-2-phenyl cyclopropane; and (±)- 1 , 1 -difluoro-2-(4-(2-(piperidin- 1 -yl)ethoxy)phenyl)-2-phenyl cyclopropane.
6. The compound according to any of claims 1 to 4, wherein the compound is (±)- 1, 1- difluoro-2-(4-(2-(morpholin-l-yl)ethoxy)phenyl)-2-phenylcyclopropane.
7. A pharmaceutical composition comprising a compound according to any of claims 1 to 6 and a pharmaceutically or therapeutically acceptable excipient or carrier.
8. Use of a compound according to any of claims 1 to 5 in the manufacture of a medicament for the treatment of a disease.
9. A compound according to any of claims 1 to 5 for use in the treatment of a disease.
10. A method of treating a disease, comprising the step of administering a compound according to any of claims 1 to 5 or a pharmaceutical composition according to claim 7 to a patient in need of same.
11. The use according to claim 8, the compound for use according to claim 9, or the method of treatment according to claim 10, wherein the disease is a neurodegenerative disorder (for example, Huntington's disease, Alzheimer's disease or Parkinson's disease), systemic lupus erythematosus ("lupus"), epilepsy, cancer, liver diseases including nonalcoholic fatty liver disease (NAFLD) and a 1 -antitrypsin deficiency (ATD), Niemann- Pick type C (NPC) disease, fibrinogen storage disease (FSB), inclusion body disease (IBD), lysosomal storage disease, muscular dystrophy (for example Duchenne muscular dystrophy or Limb-girdle muscular dystrophy), myopathy (for example myofibrillar myopathy, hereditary myopathy or diabetic cardiomyopathy), or an anti-inflammatory disorder selected from the group consisting of an autoimmune disease (for example
multiple sclerosis, rheumatoid arthritis, lupus, irritable bowel syndrome, Crohn's disease), vascular disorders (including stroke, coronary artery diseases, myocardial infarction, unstable angina pectoris, atherosclerosis or vasculitis [such as Behcet's syndrome, giant cell arteritis, polymyalgia rheumatica, Wegener's granulomatosis, Churg- Strauss syndrome vasculitis, Henoch- Schonlein purpura or Kawasaki disease]), viral infection or replication (for example infections due to or replication of viruses including pox virus, herpes virus such as Herpesvirus samiri, cytomegalovirus [CMV], hepatitis viruses or lentiviruses [including HIV]), asthma and related respiratory disorders such as allergic rhinitis and COPD, osteoporosis (low bone mineral density), tumour growth, organ transplant rejection and/or delayed graft or organ function (for example in renal transplant patients), a disorder characterised by an elevated T F-α level, psoriasis, skin wounds and other fibrotic disorders including hypertrophic scarring (keloid formation), adhesion formations following general or gynaecological surgery, lung fibrosis, liver fibrosis (including alcoholic liver disease) or kidney fibrosis, whether idiopathic or as a consequence of an underlying disease such as diabetes (diabetic nephropathy), disorders caused by intracellular parasites such as malaria or tuberculosis, neuropathic pain (such as post-operative phantom limb pain or postherpetic neuralgia), allergies, ALS, antigen induced recall response and immune response suppression.
12. A method of making a compound as defined in any of claims 1 to 6, wherein the method comprises a step of conducting a chemical reaction in a sealed tube in the presence of a reactive compound, a fluorination reagent, a catalyst and solvent, thereby making an intermediate compound for making the compound as defined in any of claims 1 to 6.
13. The method according to claim 12, wherein the intermediate compound is a difluorocyclopropane compound, for example a diphenyldifluorocyclopropane compound (such as (±)-l, l-Difluoro-2-(4-hydroxyphenyl)-2-phenylcyclo-propane).
14. The method according to claim 13, wherein the difluorocyclopropane compound is modified by substitution, for example by substituting an hydroxyl (-OH) group with an ethoxyamine basic side chain, to form a compound as defined in any of claims 1 to 6.
15. The method according to any of claims 12 to 14, wherein the chemical reaction is facilitated by heating.
16. The method according to any of claims 12 to 15, wherein the chemical reaction is facilitated by microwave radiation.
17. The method according to any of claims 12 to 16, wherein the reactive compound is 4-hydroxy-a-phenylstyrene, the fluorination reagent is trifluoromethyltrimethylsilane (TMSCF3), the catalyst is Nal and the solvent is CH3CN, and wherein the chemical reaction is optionally conducted at 80°C for example by heating for 2 hours and/or by microwave radiation for 20 min.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB2016/051794 WO2017216507A1 (en) | 2016-06-16 | 2016-06-16 | Compounds |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB2016/051794 WO2017216507A1 (en) | 2016-06-16 | 2016-06-16 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017216507A1 true WO2017216507A1 (en) | 2017-12-21 |
Family
ID=56203422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2016/051794 WO2017216507A1 (en) | 2016-06-16 | 2016-06-16 | Compounds |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2017216507A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5015666A (en) | 1982-03-30 | 1991-05-14 | Board of Reagents of the University of Oklahoma | Triarylcyclopropanes as antiestrogens and antitumor agents |
US5658914A (en) | 1980-03-07 | 1997-08-19 | Research Corporation Technologies | Diphenylcyclopropyl analogs |
US5658951A (en) | 1980-03-07 | 1997-08-19 | Research Corporation Technologies | Diphenylcyclopropyl analogs |
WO2013062079A1 (en) | 2011-10-28 | 2013-05-02 | 大正製薬株式会社 | Dihydroimidazooxazole derivative |
-
2016
- 2016-06-16 WO PCT/GB2016/051794 patent/WO2017216507A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5658914A (en) | 1980-03-07 | 1997-08-19 | Research Corporation Technologies | Diphenylcyclopropyl analogs |
US5658951A (en) | 1980-03-07 | 1997-08-19 | Research Corporation Technologies | Diphenylcyclopropyl analogs |
US5015666A (en) | 1982-03-30 | 1991-05-14 | Board of Reagents of the University of Oklahoma | Triarylcyclopropanes as antiestrogens and antitumor agents |
WO2013062079A1 (en) | 2011-10-28 | 2013-05-02 | 大正製薬株式会社 | Dihydroimidazooxazole derivative |
Non-Patent Citations (10)
Title |
---|
CHENG ET AL., MOL PHARMACOL, vol. 66, 2004, pages 970 - 977 |
DAVID GRAINGER ET AL: "Tamoxifen elevates transforming growth factor-beta and suppresses diet-induced formation of lipid lesions in mouse aorta", NATURE MEDICINE, vol. 1, no. 10, 1 October 1995 (1995-10-01), pages 1067 - 1073, XP055314628 * |
DAY ET AL., J MED CHEM, vol. 34, 1991, pages 842 - 851 |
FISCHER; WAN, J. AM. CHEM. SOC., vol. 121, 1999, pages 4555 - 4562 |
GRAINGER ET AL., NATURE MEDICINE, vol. 1, 1995, pages 1067 - 1073 |
MIYASHITA ET AL.: "Environmental Fate and Safety Management of Agrochemicals", vol. 899, 2005, AMERICAN CHEMICAL SOCIETY, pages: 159 - 166 |
OJHA; PRABHU, J. ORGANIC CHEM., vol. 77, 2012, pages 11027 - 11033 |
RECKLESS ET AL., CIRCULATION, vol. 95, 1997, pages 1542 - 1548 |
SINGH ET AL., BIOORGANIC CHEM, vol. 24, 1996, pages 81 - 94 |
WONG; FOX, 20TH INTERNATIONAL SYMPOSIUM OF FLUORINE CHEMISTRY, 22 July 2012 (2012-07-22) |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20170065540A1 (en) | Methods and compositions for treating infection | |
JP2017078082A (en) | Deuterated derivatives of Ibakaftor | |
KR900001511B1 (en) | Catechol derivatives and preventive and remedial preparation for regressive disorders | |
TW200819122A (en) | Chemical compounds | |
AU2007287338A1 (en) | Piperidine derivatives | |
US9708277B2 (en) | Inhibitors of cholesterol ester transfer protein | |
MX2015000101A (en) | Compounds and therapeutic uses thereof. | |
LU85856A1 (en) | PHENETHANOLAMINE COMPOUNDS | |
JP2014097964A (en) | Deuterated cftr potentiator | |
CN102413830A (en) | Compositions, synthesis and methods utilizing arylpiperazine derivatives | |
JPH02290841A (en) | Novel compound, its production, and pharmaceutical composition containing the same | |
US20240002385A1 (en) | Piperidinyl-methyl-purine amine d-tartaric acid salts, crystalline forms, and their use in treating medical diseases and conditions | |
RU2593500C2 (en) | New modulators of cortical dopaminergic and glutamatergic neurotransmission mediated by nmda-receptor | |
WO2023225150A1 (en) | Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions | |
WO2006118307A1 (en) | Therapeutic agent for pain | |
US5773463A (en) | Indane and tetrahydronaphthalene derivatives as calcium channel antagonists | |
JPH10509962A (en) | Use of triaryl-ethylene derivatives in the treatment and prevention of osteoporosis | |
WO2017216507A1 (en) | Compounds | |
KR20170087880A (en) | Medicine | |
JPWO2005079845A1 (en) | Migraine prophylaxis | |
US20110152227A1 (en) | Deuterium labelled derivatives of 3-(2-hydroxy-5-methyphenyl)-n,n-diisopropyl-3-phenylpropylamine and methods of use thereof | |
WO1993022302A1 (en) | N-aryloxy(thio)alkyl-azacycloalkanes useful as calcium channel antagonists | |
CN114890994A (en) | Histamine receptor antagonist and preparation thereof | |
AU2012311183A1 (en) | N- substituted benzenepropanamide and benzenepropenamide for use in the prevention or the treatment of affective disorders | |
EP4046638A1 (en) | Use of phenylquinolinones and flavonoid derivatives for treating neuropathic pain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16731959 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16731959 Country of ref document: EP Kind code of ref document: A1 |